Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

63.04
-6.0700-8.78%
Post-market: 63.040.00000.00%17:00 EDT
Volume:38.14K
Turnover:2.45M
Market Cap:86.49M
PE:-1.24
High:70.25
Open:69.00
Low:61.39
Close:69.11
52wk High:240.00
52wk Low:4.28
Shares:1.37M
Float Shares:850.80K
Volume Ratio:0.80
T/O Rate:4.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-50.8300
EPS(LYR):-96.3944
ROE:-109.24%
ROA:-36.41%
PB:2.03
PE(LYR):-0.65

Loading ...

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

THOMSON REUTERS
·
Mar 09

Spruce Biosciences CEO Javier Szwarcberg to Present at Leerink Global Healthcare Conference and The Citizens Life Sciences Conference

Reuters
·
Mar 03

Spruce Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 19

Regulatory De-Risking and Extended Runway Underpin Maintained Buy Rating on Spruce Biosciences

TIPRANKS
·
Feb 19

Spruce Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $200 From $220

THOMSON REUTERS
·
Feb 19

Spruce Biosciences Shares Rise 8.16% After Co Moves Towards FDA Filing for Rare Childhood Brain Disorder Drug

THOMSON REUTERS
·
Feb 18

BUZZ-Spruce Biosciences jumps as co moves toward FDA filing for rare childhood brain disorder drug

Reuters
·
Feb 18

Spruce Biosciences Advances TA-ERT BLA Plan for Sanfilippo Syndrome Type B Following FDA Type B Meetings

Reuters
·
Feb 18

Spruce Biosciences Announces Positive Type B Meetings With U.S. FDA for Ta-Ert for the Treatment of Sanfilippo Syndrome Type B (Mps Iiib)

THOMSON REUTERS
·
Feb 18

Spruce Biosciences Inc - Ta-Ert Bla Submission Anticipated in Q4

THOMSON REUTERS
·
Feb 18

Spruce Biosciences CEO to Participate in Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Feb 18

Spruce Biosciences Reports Long-Term Efficacy of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters
·
Feb 06

Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team

Reuters
·
Feb 03

Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters
·
Jan 28

Top Premarket Gainers

MT Newswires Live
·
Jan 26

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Benzinga
·
Jan 21

Harbour BioMet acquires common stock in Spruce Biosciences

TIPRANKS
·
Jan 20

HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise

TIPRANKS
·
Jan 19

HBM Holdings Acquires 3.8% Stake in Spruce Biosciences

Reuters
·
Jan 19

BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue Capital

Reuters
·
Jan 08